Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 10, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Oren Livnat Reiterated (XERS) at Strong Buy and Held Target at $6 on, May 10th, 2023
Oren Livnat of HC Wainwright & Co., Reiterated "Xeris Biopharma Holdings, Inc." (XERS) at Strong Buy and Held Target at $6 on, May 10th, 2023.
Oren has made no other calls on XERS in the last 4 months.
There is 1 other peer that has a rating on XERS. Out of the 1 peers that are also analyzing XERS, 0 agree with Oren's Rating of Hold.
This is the rating of the analyst that currently disagrees with Oren
- Roanna Ruiz of "SVB Leerink" Maintained at Buy with Decreased Target to $5 on, Friday, January 27th, 2023
